Specialties

Rethinking immune rechallenge: Tivozanib monotherapy emerges as a promising post-ICI option in metastatic RCC

Presented By

Prof. Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, TiNivo-2

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:52

Faecal transplants show promise in enhancing metastatic RCC treatment

Presented By

Dr Chiara Ciccarese, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:44

More highlights in Renal Cell Carcinoma

Trial

LITESPARK-005, SUNNIFORECAST

Type

Peer-reviewed article

4 November 2024 11:42

TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?

Presented By

Dr Gianluca Ianiro, Agostino Gemelli University Policlinic, Italy

Trial

Phase 2, TACITO

Conference

UEGW 2024

Type

News article

15 October 2024 10:13

Biomarkers for treatment of renal cell carcinoma

Trial

Phase 3, CLEAR, KEYNOTE-426, IMmotion010

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:00

Subcutaneous nivolumab may benefit patients across many indications

Expert

Dr Saby George, Roswell Park Cancer Institute, Buffalo, NY, USA

Trial

Phase 3, CheckMate 67T

Conference

ASCO GU 2024

17 July 2024 12:37

CircPRELID2 promotes renal cell carcinoma via miR-22-3p/ETV1 cascade

14 June 2024 13:52

Minimal incidence of severe end-stage kidney disease following SABR for localised primary kidney cancer

14 June 2024 13:50

Comparing standard and modified ipilimumab with nivolumab in advanced renal cell carcinoma treatment

14 June 2024 13:48

IMmotion010 trial: KIM-1 and disease-free survival in RCC

Presented By

Prof. Laurence Albiges, Institut Gustave Roussy, France

Trial

Phase 3, IMmotion010

Conference

ASCO 2024

13 June 2024 15:07

Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC

Presented By

Dr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran

Trial

Phase 1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:11

The road to improving doctor-patient interactions in kidney cancer

Expert

Dena Battle , KCCure - Kidney Cancer Research Alliance, USA

12 June 2023 10:37

KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-564

Conference

EAU 2022

Type

News article

22 July 2022 12:22

Fewer complications with robotic surgery in renal cancer

Presented By

Prof. Marc-Oliver Grimm, Universitätsklinikum Jena, Germany

Trial

Phase 3, OpeRa

Conference

EAU 2022

Type

News article

22 July 2022 12:19

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By

Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NeoAvAx

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By

Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-RCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By

Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Trial

Phase 1/2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Folliculin mutations not associated with sporadic chromophobe RCC

Presented By

Dr Joseph Jacob, Upstate University Hospital, NY, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Differential patterns of molecular alterations among sites of metastasis in RCC

Presented By

Dr Rana McKay, University of California San Diego, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By

Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA

Trial

Phase 2, HCRN GU16-260

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Stereotactic radiotherapy with pembrolizumab promising for oligometastatic kidney cancer

Journal

European Urology

29 December 2021 17:04

Immunotherapy combo fails to improve overall survival in advanced kidney cancer

Journal

JAMA Oncology

27 December 2021 17:24

Belzutifan shows benefit in two conditions that spark tumor growth

Journal

The New England Journal of Medicine

24 November 2021 23:00

TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

Presented By

Prof. Janet Brown, University of Sheffield, UK

Trial

Phase 2, STAR

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Presented By

Dr Naveen Vasudev, St James University Hospital, UK

Trial

Phase 2, PRISM

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Cabozantinib an option for kidney cancer with brain metastases

Journal

JAMA Oncology

29 October 2021 21:14

Best of EAU: Immune cell populations have prognostic value in RCC

Presented By

Dr Alberto Breda, Autonomous University of Barcelona, Spain

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

KEYNOTE-564: First positive phase 3 results with adjuvant checkpoint inhibition in RCC

Presented By

Prof. Thomas Powles, Barts Cancer Centre, London, UK

Trial

Phase 3, KEYNOTE-564

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

PSMA PET-CT more accurate than standard-of-care imaging in RCC

Presented By

Dr Arsalan Tariq , Royal Brisbane and Women's Hospital, Australia

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

Worse renal function after radical versus partial nephrectomy

Presented By

Prof. Francesco Trevisani, IRCCS Ospedale San Raffaele, Milan, Italy

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:28

Post-nephrectomy pembrolizumab improves disease-free survival

Presented By

Dr Toni Choueiri , Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE 564

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:23

Glutaminase inhibitor telaglenastat does not improve survival mRCC

Presented By

Dr Nizar Tannir, Houston University, TX, USA

Trial

Phase 3, CANTATA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:26

Lenvatinib-pembrolizumab combo promising in advanced kidney cancer

Journal

The Lancet Oncology

5 July 2021 16:35

Single-cell mRNA signaling facilitates diagnosis of childhood and adult kidney tumors

Journal

Nature Communications

1 July 2021 19:24

Post-surgery immunotherapy could be new standard of care in common kidney cancer

Conference

American Society of Clinical Oncology annual meeting

4 June 2021 16:19

Upfront lenvatinib-everolimus combo promising in kidney cancer

Journal

European Urology

28 May 2021 17:17

CLEAR trial: promising new combination to treat RCC

Presented By

Dr Alain Ravaud, Centre Hospitalier Universitaire de Bordeaux, France

Trial

Phase 3, CLEAR

Journal

Physician’s Weekly

Conference

ASCO GU 2021

15 April 2021 16:19

CheckMate 9ER offers RCC new frontline option

Presented By

Prof. Toni Choueiri , Dana Farber Cancer Institute, Harvard University, Boston, USA

Trial

Phase 3, CheckMate 9ER

Journal

Physician's Weekly

Conference

ESMO Virtual Congress 2020

13 April 2021 16:01

ASCO-GU Highlight: Cabozantinib plus nivolumab provides better QoL than sunitinib

Presented By

Dr. David Cella , Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA

Trial

Phase 3, CheckMate-9ER

Journal

Physician’s Weekly

Conference

ASCO GU 2021

13 April 2021 15:44

Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC

Presented By

Prof. David Cella, Robert H. Lurie Comprehensive Cancer Centre, Northwestern University, Illinois, USA

Trial

Phase 3, CheckMate 9ER

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma

Presented By

Dr Robert Motzer, Memorial Sloan Kettering Cancer Centre, New York, USA

Trial

Phase 3, CLEAR

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Inflammatory markers may guide treatment decisions in metastatic renal cell cancer

Presented By

Ms Vishwani Chauhan, University of Edinburgh, UK

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?

Presented By

Dr Diana Maslov, Ochsner Health System, Louisiana, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Axitinib offers hope for improving renal cell cancer surgical outcomes

Presented By

Prof. Grant Stewart, University of Cambridge, UK

Trial

Phase 2, NAXIVA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:53

Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma

Presented By

Dr Jonathan Thouvenin, Institut de Cancerologie Strasbourg Europe, France

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Predictors of oral anti-cancer agent utilisation in renal cell carcinoma

Presented By

Prof. Stephanie Wheeler, University of North Carolina, USA

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma

Presented By

Dr Craig Gedye, Calvary Mater Newcastle, Australia

Conference

ASCO GU 2021

Type

Peer-reviewed article

24 March 2021 14:52

High BMI tied to better overall survival in immune checkpoint inhibitor-treated metastatic RCC

Journal

JAMA Oncology

12 March 2021 23:31

Nivolumab-cabozantinib combo boosts survival over sunitinib in kidney cancer

Journal

The New England Journal of Medicine

3 March 2021 23:00

Chronic kidney disease patients need close monitoring during Ramadan fast

Journal

Clinical Kidney Journal

19 February 2021 23:32

Cabozantinib the new reference standard in metastatic papillary kidney cancer

Journal

Lancet

16 February 2021 21:13

Details released for CLEAR study on advanced renal cell carcinoma

Journal

The New England Journal of Medicine

13 February 2021 19:00

ACE2-generated small peptide shows promise in clear-cell kidney cancer

Journal

Science Translational Medicine

27 January 2021 23:11

Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk -study

21 September 2020 17:26

Timing of radiation plus immunotherapy could be key to antitumor response in kidney cancer

Journal

PNAS

15 September 2020 23:16

Timing of radiation plus immunotherapy could be key to antitumor response in kidney cancer

Journal

PNAS

15 September 2020 23:16

KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib

Presented By

Prof. Jens Bedke, University of Tübingen, Germany

Trial

Phase 3, KEYNOTE-426

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 10:41

Debate: upfront cytoreductive nephrectomy or not?

Presented By

Prof. Axel Bex & Prof. Antonio Finelli

Trial

Phase 3, CARMENA; SURTIME

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 09:29

Robotic-assisted partial nephrectomy: lower morbidity

Presented By

Dr Alessandro Larcher, Ospedale San Raffaele, Italy

Trial

IRON

Conference

EAU 2020

Type

Peer-reviewed article

20 August 2020 09:22

Novel mode of action for kidney cancer treatment

Presented By

Prof. Eric Jonasch, MD Anderson Cancer Center, Houston, USA

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 14:24

Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours

Presented By

Prof. Bernhard Escudier, Gustave Roussy Cancer Campus, Paris, France

Trial

CheckMate 214

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 12:49

Renal transplantation

Presented By

Dr Mireia Musquera, Dr Mark Sullivan

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 23:08

Renal cell carcinoma

Trial

OpeRA

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 21:16